NuCana posted a net loss of £3.1 million for Q2 2026, narrowing from a £24.1 million loss a year earlier.
Operating loss narrowed to £3.55 million from £11.83 million, while R&D expense fell to £2.25 million from £7.1 million.
Cash and cash equivalents slipped to £19.5 million at June 30 from £24.3 million at Dec. 31, 2025.
Pipeline update and outlook
Recruitment was completed in the NuTide:701 Phase 2 expansion of NUC-7738 with Keytruda in PD-1 inhibitor-resistant metastatic melanoma; final data are still slated for 2026.
Cash runway is expected to extend into 2029; FDA dialogue is ongoing on a potential registrational strategy for NUC-7738 in melanoma.
NCNA•
